Dosimetric parameters predicting grade ≥3 acute oral mucosal toxicity induced by radiation:an independent validation study comparing oral cavity versus mucosal surface contouring
Li Kaixin, Chen Yuanyuan, Hu Qiaoying, Chen Ming, Xing Peiling
Department of Radiation Oncology,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,China (Li KX,Xin PL);Department of Radiation Oncology,Zhejiang Tumor Hospital,Zhejiang Provincial Key Laboratory of Radiotherapy,Hangzhou 310000,China (Chen YY,Hu QY,Chen M)
Abstract：Objective To investigate whether the mucosal surface volume can be an alternative to the oral cavity volume for predicting grade 3/4 acute oral mucosal toxicity in patients with locally advanced nasopharyngeal carcinoma (LANPC). Methods A total of 92 patients with LANPC who underwent intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy were enrolled in this study. The delineation of the oral mucosa was performed using oral cavity contours (OCC) or mucosal surface contours (MSC). Dosimetric comparisons of toxicity were performed based on the obtained dose-volume histograms (DVHs). The receiver operating characteristic (ROC) curve and logistic regression analysis were used to do statistical analysis of the data obtained from the two different contour methods. Results Both contouring methods showed a significant dose-volume association between oral mucosal exposure and acute oral mucosal toxicity. Logistic regression analysis showed that body weight loss was the independent associated factor for grade 3/4 toxicity in both OCC group and MSC group (P=0.017 and 0.005). And the independent correlation factors for dosimetric parameters in OCC group and MSC group were V30(P=0.003) and V50(P=0.003), respectively. The area under the ROC curve (AUC) of OCC at V30 was 0.753(P=0.001) and the AUC of MSC at V50 was 0.714(P=0.004). Conclusions DVH analysis of mucosal surface volume can accurately predict grade ≥3 oral mucosal toxicity in patients with LANPC who receive IMRT and concurrent chemotherapy. However, OCC is superior to MSC in clinical application.
[1] Peterson DE,Boers-Doets CB,Bensadoun RJ,et al. Management of oral and gastrointestinal mucosal injury:ESMO clinical practice guidelines for diagnosis,treatment,and follow-up[J].Ann Oncol,2015,26(S5):139-151.DOI:10.1093/annonc/mdv202. [2] Narayan S,Lehmann J,Coleman MA,et al. Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,72(3):756-762.e4.DOI:10.1016/j.ijrobp.2008.01.060. [3] Wang ZH,Zhang SZ,Zhang ZY,et al. Protecting the oral mucosa in patients with oral tongue squamous cell carcinoma treated postoperatively with intensity-modulated radiotherapy:a randomized study[J].Laryngoscope,2012,122(2):291-298.DOI:10.1002/lary.22434. [4] Mazzola R,Ricchetti F,Fersino S,et al. Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment:a dose-volume analysis[J].Head Neck,2016,38(S1):E815-E819.DOI:10.1002/hed.24106. [5] Musha A,Shimada H,Shirai K,et al. Prediction of acute radiation mucositis using an oral mucosal dose surface model in carbon ion radiotherapy for head and neck tumors[J/OL].PLoS One,2015,10(10):e0141734.DOI:10.1371/journal.pone.0141734. [6] Sun Y,Yu XL,Luo W,et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy[J].Radiother Oncol,2014,110(3):390-397.DOI:10.1016/j.radonc.2013.10.035. [7] Dean JA,Welsh LC,Gulliford SL,et al. A novel method for delineation of oral mucosa for radiotherapy dose-response studies[J].Radiother Oncol,2015,115(1):63-66.DOI:10.1016/j.radonc.2015.02.020. [8] 中国鼻咽癌临床分期工作委员会.2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001.Clinical staging Committee of nasopharyngeal carcinoma in China. Expert consensus on target area and dose design guideline of intensity modulated radiotherapy for nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2011,20(4):267-269.DOI:10.3760/cma.j.issn.1004-4221.2011.04.001. [9] Liu ZG,Zhao Y,Tang J,et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:a retrospective analysis[J].Oncotarget,2016,7(17):24429-24435.DOI:10.18632/oncotarget.8225. [10] Li CJ,Wang SZ,Wang SY,et al. Assessment of the effect of local application of amifostine on acute radiation-induced oral mucositis in guinea pigs[J].J Radiat Res,2014,55(5):847-854.DOI:10.1093/jrr/rru024. [11] Wu SX,Cui TT,Zhao C,et al. A prospective,randomized,multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma[J].Radiother Oncol,2010,97(1):113-118.DOI:10.1016/j.radonc.2010.08.003. [12] Antin JH,Lee SJ,Neuberg D,et al. A phase Ⅰ/Ⅱ double-blind,placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation[J].Bone Marrow Transplant,2002,29(5):373-377.DOI:10.1038/sj.bmt.1703394. [13] Ueno D,Sato J,Igarashi C,et al. Accuracy of oral mucosal thickness measurements using spiral computed tomography[J].J Periodontol,2011,82(6):829-836.DOI:10.1902/jop.2010.100160.
2017, Vol. 26 
